Lincoln Pharmaceuticals Operational Benchmarking
₹562.75-0.20%close, 9 Oct 2026
- Market cap
- ₹1,127 crore
- P/E
- 22.5
- P/B
- 2.85
- ROE
- 14.5%
- Dividend yield
- 1.20%
- 52-week range
- ₹405.18 – ₹759.71
Lincoln Pharmaceuticals compared with sector peers on revenue, market capitalization, valuation, and return metrics.
Lincoln Pharmaceuticals sector benchmarking & peer comparison
Operational and financial KPI comparison against sector peers.
| Company | LTP (₹) | P/E | Market Cap (₹ cr) | Div Yield | Qtr Sales (₹ cr) | ROCE % |
|---|---|---|---|---|---|---|
| Lincoln Pharmaceuticals Limited | ₹562.75 | 22.5 | 1,127 | 1.2% | 282 | 14.5% |
| Median (1 Cos) | ₹562.75 | 22.5 | 1,127 | 1.2% | 282 | 14.5% |
Source: NSE sector index filings and financial statements. Data as of 9 October 2026. How this data is compiled.
Same Data For Peers
Trade Lincoln Pharmaceuticals With ATS
Track LINCOLN live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.